ESCRT-II plays a pivotal role in receptor downregulation and multivesicular body biogenesis and is conserved from yeast to humans. The crystal structures of two human ESCRT-II complex structures have been determined at 2.6 and 2.9 Å resolution, respectively. The complex has three lobes and contains one copy each of VPS22 and VPS36 and two copies of VPS25. The structure reveals a dynamic helical domain to which both the VPS22 and VPS36 subunits contribute that connects the GLUE domain to the rest of the ESCRT-II core. Hydrodynamic analysis shows that intact ESCRT-II has a compact, closed conformation. ESCRT-II binds to the ESCRT-I VPS28 C-terminal domain subunit through a helix immediately C-terminal to the VPS36-GLUE domain. ESCRT-II is targeted to endosomal membranes by the lipid-binding activities of both the Vps36 GLUE domain and the first helix of Vps22. These data provide a unifying structural and functional framework for the ESCRT-II complex.
INTRODUCTION
The ESCRT (endosomal sorting complex required for transport) machinery directs the budding of intralumenal vesicles from the limiting membrane of endosomes to form multivesicular bodies (MVBs) in yeast, insect, and animal cells (Babst, 2005; Hurley, 2008; Saksena et al., 2007; Williams and Urbe, 2007) ; the budding of HIV-1 and other enveloped viruses from the plasma membrane of animal cells (Bieniasz, 2006) ; and the membrane abscission step in cytokinesis (Carlton and Martin-Serrano, 2007; Morita et al., 2007) . ESCRT-I and ESCRT-II are soluble and constitutively assembled complexes, which are targeted to the endosomal membrane by interactions with membranebound phosphoinositides and ubiquitinated membrane proteins (Babst, 2005; Hurley, 2008; Saksena et al., 2007; Williams and Urbe, 2007) . ESCRT-III assembles into an insoluble array on the endosomal membrane and is thought to play a key role in membrane deformation (Babst, 2005; Hurley, 2008; Saksena et al., 2007; Williams and Urbe, 2007) . ESCRT-III monomers are thought to be targeted to endosomes in part by interactions with ESCRT-II (Bowers et al., 2006; Langelier et al., 2006; MartinSerrano et al., 2003; Teo et al., 2004; von Schwedler et al., 2003; Yorikawa et al., 2005) , among other factors. Thus, ESCRT-II connects the upstream cargo-binding components of the system with the downstream membrane-remodeling machinery.
In yeast, ESCRT-II is required for the lysosomal degradation of the mating-factor receptor Ste2 (Babst et al., 2002) , among other cargo. In Drosophila, the ESCRT-II subunit VPS25 acts as a tumor suppressor by promoting the degradation of the Notch and DPP receptors (Herz et al., 2006; Thompson et al., 2005; Vaccari and Bilder, 2005) . In human cells, ESCRT-II is required for the degradation of internalized EGF receptors (Langelier et al., 2006; Malerod et al., 2007) , the chemokine receptor CXCR4 (Malerod et al., 2007) , and ferroportin (De Domenico et al., 2007) . ESCRT-II has at least one clear-cut nonendosomal role in establishing the bicoid mRNA gradient (Irion and St Johnston, 2007) . In another potential nonendosomal function, the subunits of human ESCRT-II associate with the ELL transcriptional elongation complex (Kamura et al., 2001) , although the implications of this are largely unexplored. Furthermore, ESCRT-II is responsible for connecting MVBs to the Rab7 effector RILP (Progida et al., 2006; Wang and Hong, 2006) , which in turn binds to the dynein-dynactin motor complex and may coordinate MVB biogenesis to dynein-mediated motility (Progida et al., 2007) .
ESCRT-II is targeted to endosomal membranes, binds ubiquitinated cargo, and assembles with other ESCRT complexes through interdependent interactions. The N-terminal region of Vps36 contains a phosphoinositide-binding GLUE domain (Slagsvold et al., 2005; Teo et al., 2006) important for membrane targeting. The yeast Vps36 GLUE domain contains a large sequence insert comprising two Npl4-type zinc finger domains, NZF1 and NZF2. The structure of the former has been determined in complex with the C-terminal domain of yeast Vps28 (Gill et al., 2007) , a subunit of ESCRT-I. However, human VPS36 lacks this domain, and the nature of its interaction with ESCRT-I is unknown. The complex of the yeast VPS36 NZF2 with its ligand, ubiquitin, has been modeled on the basis of an NMR structure of the Npl4 zinc finger bound to ubiquitin (Alam et al., 2004) . Human VPS36 also binds to ubiquitin, but it does so via a nonconserved site on the GLUE domain (Alam et al., 2006; Hirano et al., 2006; Slagsvold et al., 2005) .
The core of the yeast ESCRT-II complex is shaped like the letter ''Y'' and contains two copies of the Vps25 subunit and one copy each of the Vps22 and Vps36 subunits (Hierro et al., 2004; Teo et al., 2004) . The N termini of the Vps22 and Vps36 subunits project from the ordered core of the complex. The N terminus of Vps22 contains a long helical region of unknown function. A $100 residue predicted helical region of unknown structure and function connects the Vps36 GLUE domain to the core. Structural information has been rapidly accumulating for most of the ESCRT components, allowing, for example, the reconstruction of a hydrodynamic model of intact ESCRT-I from the crystal structures of the constituent fragments (Kostelansky et al., 2007) . The main obstacle to a similar model for the intact ESCRT-II has been the lack of information on the $100 residue helical connector in Vps36 and the N-terminal helical region of Vps22. Here, we report the structures of two human ESCRT-II constructs that include these regions. These two regions fold into a compact helical bundle, except for the N-terminal $25 amino acids of Vps22, which we find has a role in membrane targeting. On the basis of this and previous structures (Alam et al., 2006; Hirano et al., 2006) and hydrodynamic measurements, we develop a unified model for the structure of intact ESCRT-II. We extend the observation on the N terminus of Vps22 to develop a model of dual membrane targeting by this region and the GLUE domain.
RESULTS
Crystallographic Analysis of Human ESCRT-II The 2.6 Å crystal structure of the human ESCRT-II complex lacking the GLUE domain was solved by multiple isomorphous replacement (form I: Table 1 ; Figures 1A-1D ). The complex contains two molecules of VPS25, one molecule of VPS22, and one copy of VPS36. It has a trilobal shape similar to that of yeast ESCRT-II (Hierro et al., 2004; Teo et al., 2004;  Figure S1 , see the Supplemental Data available with this article online). Two of the lobes consist of VPS25 subunits, and the third consists of VPS36 and VPS22 (Figures 1B and 1C) . The VPS22 and VPS36 subunits form a roughly parallel side-to-side arrangement. There is an extensive interface between VPS22 and VPS36, with a buried surface area of 2225 Å 2 . The first four helices of VPS22 and the first three helices VPS36 in this structure form a novel helical domain (HD) (Figure 2A ). This conserved helical domain was absent in the structure of yeast ESCRT-II because the sequences corresponding to the first three helices of Vps36 were absent from the crystallized portion of yeast ESCRT-II ( Figure 1A ; Hierro et al., 2004; Teo et al., 2004) . The HD is one of the most mobile The values in parentheses relate to highest resolution shells. a R sym = S h S i jI i (h) À < I > j / S h S i I i (h), where I is the observed intensity and < I > is the average intensity of multiple observations of symmetry-related reflections. b R = SjjF o j À kjF c jj /SjF o j, where F o and F c are observed and calculated structure factor amplitudes, respectively. c R free is calculated for a randomly chosen 5% of reflections; the R factor is calculated for the remaining 95% of reflections used for structure refinement. d Average B value of all atoms in an asymmetric unit. regions of the human ESCRT-II crystal structure. Indeed, the HD helices of VPS22 and VPS36 subunits have sausage-like electron density. The presence of a few protruding bulky side chains allowed for sequence assignment. The linker connecting helices H1 and H2 (residues 202-211) in the VPS36 subunit was not visible in the structure. The overall B value of the ESCRT-II core complex is 78.7 Å 2 . However, the average B value of the HD is 124.7, compared to an average B value of 61.2 Å 2 for the remainder of the structure ( Figure 1E , left hand panel). This suggested to us that the HD was either loosely packed in the crystal lattice or that it had intrinsically high mobility. VPS22, VPS25 and VPS36 each contain two repeats of a winged helix (WH) domain with an H1/b1/H2/H3/b2/b3 topology. The N-terminal WH domain (WH1) packs against the C-terminal WH domain (WH2) in a head-to-tail manner. All of the WH domains in the ESCRT-II complex superimpose on each other with an rmsd of less than 2 Å , although there is no recognizable sequence similarity between the subunits.
The N-terminal domain of one VPS25 subunit contacts the C-terminal domain of VPS22, and the other VPS25 subunit contacts both VPS36 and VPS22. The VPS25 subunit buries 762 Å 2 (63 Å 2 for VPS22) of surface area upon binding to VPS36, and the other VPS25 subunit buries 1149 Å 2 of surface area upon binding to VPS22 and VPS36. The WH2 domain of the VPS36-proximal VPS25 subunit, which packs in the crystal lattice along the c-axis, appears to be completely disordered and could not be visualized in an electron density map. This suggested to us that VPS25 has intrinsic flexibility between its two WH domains. The N-terminal 25 residues of VPS22 contain 8 basic charged residues and are predicted to form an a helix ( Figure S2 ). We refer to this predicted helix as VPS22-H0. The linker between the GLUE domain and the C-terminal core of VPS36 (residues 140-169) also contains a predicted a helix, which we refer to as VPS36-H0 ( Figure 2D ). In an effort to reveal the structure of these N-terminal regions of VPS22 and VPS36 and to obtain more detailed information on the HD, we determined the 2.9 Å crystal structure (form II, Table 1 ) of a second construct (construct a, Figure 3C ). The flexible WH2 domain of VPS25 was deleted in the second construct in an attempt to generate more ordered crystals. The structures of forms I and II are almost identical with an rmsd of 1.25 Å 2 . Form II manifested better electron density in the HD. It was possible to visualize the linker between H1 and H2 of VPS36. The improved density also allowed us to confirm the assignment of amino acids in the HD. The VPS22-H0, VPS36-H0, and adjoining residues were disordered. A solvent channel takes the space that is presumably occupied by the disordered N-terminal region in the crystal. The average B value of HD is 101.6 Å 2 , which is higher than the value of 79.1 Å 2 for the remainder of the structure, although lower than the HD in form I ( Figure 1E ). The finding that the HD region has such high B factors in two different crystal forms leads us to conclude that this domain is inherently dynamic.
Solution Conformation of the Complete ESCRT-II Complex
To investigate the conformation of the full-length ESCRT-II complex in solution, we measured the Stokes radii R H of various ESCRT-II constructs. The Stokes radii of the constructs were obtained using size exclusion chromatography (SEC) calibrated with standards of known R H ( Figure 3A ). To gain insight on the overall shape of full-length ESCRT-II, we positioned the GLUE domain structure (Alam et al., 2006; Hirano et al., 2006) based on the R H values from SEC experiments ( Figures 3A and 3B ). The position of the GLUE domain was adjusted until the calculated R H agreed with the experimental values to within 0.1 nm.
Conformations involving an extended linker between the crystallized core and the GLUE domain can be ruled out because these predict R H values substantially higher than are actually observed ( Figure S3 ). On the other hand, conformations in which the GLUE domain is packed against the WH domains lead to predicted R H values that are lower than the experimental value. Based on this exercise, we concluded that the GLUE domain is probably packed against the HD domain of the crystallized ESCRT-II core and that human ESCRT-II is in a compact, closed conformation in solution ( Figure 3B ).
Interactions between Human ESCRT-I and ESCRT-II
The yeast ESCRT-I interacts with ESCRT-II via the C-terminal domain (CTD) of Vps28 (Kostelansky et al., 2006; Teo et al., 2006) and the NZF1 domain of Vps36 (Gill et al., 2007; Teo et al., 2006) . However, human ESCRT-II contains no NZF domains. Evidence for binding between human ESCRT-I and II comes from yeast two-hybrid analyses of pairwise interactions 
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Structure and Targeting of Human ESCRT-II between subunits of ESCRT-I and II (Langelier et al., 2006) . However, isolated ESCRT subunits expressed for two-hybrid studies contain extensive unpartnered hydrophobic regions. Under physiological conditions, these would be buried within the larger complex. Given the presence of significant conserved sequences on the surface of the Vps28 CTD (Gill et al., 2007; Pineda-Molina et al., 2006) and 36% sequence identity between the yeast and human CTD sequences, we speculated that this domain might have a conserved role in binding to ESCRT-II. Thus, we sought to revisit the interaction between human ESCRT-I and II using the purified, stable, independently folded VPS28 CTD and various forms of the purified, fully assembled ESCRT-II complex in direct binding assays ( Figures 3C and 3D ). The full-length ESCRT-II construct binds to VPS28-CTD, but not to the GST control ( Figure 3D ). Constructs in which the GLUE domain, the VPS25 WH2 domain, and VPS22-H0 (constructs a, d, e, and f, Figure 3D ) were deleted, respectively, also bind to the VPS28-CTD. However the constructs lacking residues 149-169, which encompass VPS36-H0, did not interact with VPS28-CTD, suggesting that the VPS36-H0 and/or adjacent residues are required for binding to the VPS28-CTD. The role of this region of VPS36 is consistent with the two-hybrid analysis (Langelier et al., 2006) . In order to pinpoint this site, two blocks of conserved residues were mutated to polyalanine. A quadruple mutant within VPS36-H0 (construct m2), IERK(159-162)AAAA, showed substantially reduced binding as compared to wild-type and to another, mutant (construct m1, Figure 3C ). GST-tagged constructs of short regions of VPS36 (residues 147-171 and residues 147-201) were made to test if these isolated regions were sufficient for binding. These constructs did not pull down VPS28-CTD ( Figures 3C and 3D) , nor did the isolated GLUE domain ( Figure 3C ; data not shown). Thus, VPS36-H0 is necessary but not sufficient for interaction with the VPS28-CTD. We sought to characterize the conformation of the VPS28-CTD-ESCRT-II complex in solution. The mixture of these two normally soluble proteins resulted in their precipitation. The simplest interpretation is that the binding of the VPS28-CTD and ESCRT-II leads to a conformational change in one or both partners.
Determinants for Membrane Targeting of Human ESCRT-II
To investigate the lipid specificity and membrane binding sites in human ESCRT-II, we tested binding of various ESCRT-II constructs to lipid vesicles of various compositions (Figure 4 ). For expediency, we used a pseudo-intact ESCRT-II (construct f, Figure 3C ) lacking the VPS25-WH2 as the baseline for comparison. This construct bound to vesicles as well as, or better than, the intact complex ( Figure S4 ), and we found that it was more stable and could be purified with several-fold higher yields than the intact complex. The following deletion constructs were made in the context of this pseudo-intact complex: a deletion of GLUE domain (construct e), a deletion of the basic N-terminal 24 residues (D1-24) of VPS22 (construct h), and a double deletion of both the GLUE and VPS22-H0 (construct c). The purified pseudo-intact ESCRT-II showed strong binding to liposomes made of synthetic lipids composed of phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphoinositides (PIPs) (Figures 4D-4K ) and bound weakly to PC:PE and PC:PE: phosphatidylinositol (PI) liposomes ( Figures 4B, 4C, and 4K) . Deletion of the VPS22-H0 (construct h) significantly decreased the membrane binding to all PIPs tested. However, deletion of VPS22-H0 had no apparent effect on binding to PC:PE liposomes ( Figures 4B and 4K) . The GLUE domain deletion lost binding to PC:PE and PC:PE:PI ( Figures 4B, 4C , and 4K). Deletion of both GLUE and D1-24 of VPS22 (construct c) essentially abolished binding to all compositions tested ( Figures 4B-4K) . From these data, we draw the following conclusions. Human ESCRT-II binds strongly but relatively promiscuously to PIPs and binds weakly to uncharged lipids. Both the GLUE domain and VPS22-H0 are required for full membrane binding.
A Functional Role for Vps22-H0
The Vps22-H0 is conserved from yeast to humans, with 30% sequence identity between these two species in this region ( Figure S2 ). To determine if the Vps22-H0 was important for the cargo sorting function of ESCRT-II in vivo, the localization of the ESCRT substrate Cps1 was assayed in yeast expressing wildtype and mutant alleles of vps22. Yeast Vps22 contains 9 basic charged residues in the N-terminal 50 residues. To test the contribution of the N-terminal region of Vps22 on cargo-sorting function in vivo, we constructed an N-terminal 30 residue deletion mutant, Vps22 D1-30 ( Figure S2 ). As expected (Babst et al., 2002) , vps22D manifests GFP-Cps1 mislocalized to a prominent class E compartment and is absent from the vacuolar lumen ( Figure 5B ). The wild-type phenotype is completely rescued by a plasmid bearing wild-type VPS22 ( Figure 5E ). Expression of VPS22 D1-30 results in some vacuolar GFP-Cps1 localization ( Figure 5F ) but most of the cargo is retained on the limiting membrane, consistent with a weak class E phenotype. This indicates that the Vps22-H0 is important for the cargo-sorting function of ESCRT-II.
We next sought to determine if Vps22-H0 cooperated with the Vps36-GLUE domain in function. The yeast Vps36 GLUE domain PI(3)P binding pocket double-mutant VPS36 R89A/R261A has a strong class E phenotype (Teo et al., 2006) . We found that the single GLUE domain mutants VPS36 R89A and VPS36
R261A
expressed in a vps36D background had near normal and normal function, respectively ( Figures 5H and 5I ). However, when either of these mutants is coexpressed with VPS22 D1-30 in a vps22D vps36D background, a strong class E phenotype is observed ( Figures 5K and 5L) . The loss of function is much stronger than for any of the individual mutants, consistent with the concept that the Vps22-H0 and the Vps36-GLUE domain cooperate in the sorting function of ESCRT-II.
In order to determine if the defects in sorting were due to changes in membrane targeting, the localization of wild-type and mutant Vps22-GFP constructs was evaluated ( Figures 5M-5S ). (A) The ESCRT-II constructs used for liposome binding assay are shown for reference. All constructs used for the binding assay lack the VPS25-WH2 for expedience. However, the binding of this construct and full-length ESCRT-II are essentially identical ( Figure S3 ). dissociation of ESCRT components from endosomal compartments is inhibited, allowing their endosomal localization to be monitored. Consistent with previous results (Babst et al., 2002) , Vps22-GFP was diffusely distributed in a vps22D background ( Figure 5M ) but found in large punctate structures in a vps4D vps22D vps36D strain ( Figure 5N ). The single GLUE domain mutants VPS36 R89A and VPS36 R261A manifested, respectively, complete and predominant punctate localization of Vps22-GFP in the vps4D vps22D vps36D strain ( Figures 5P and 5Q) . Therefore, these mutations did not substantially impair ESCRT-II targeting. The VPS22
D1-30
-GFP allele manifested mostly punctate localization, with a small increase in diffuse localization compared to wildtype VPS22 ( Figure 5O ). The VPS22 D1-30 -GFP allele in combination with either VPS36 R89A or VPS36
R261A
, however, showed a completely diffuse localization pattern ( Figures 5R and S5) . Thus, these defects in the Vps22-H0 and GLUE domain abolish endosomal localization of ESCRT-II only in combination.
DISCUSSION
A major goal of structural analysis is to obtain a holistic picture of molecular assemblies. This is typically accomplished by integrating high-resolution X-ray and NMR structures of smaller fragments with lower resolution data on the intact complex using electron microscopy or solution-state techniques. In the case of ESCRT-II, atomic structures have been available for the WH domain core (Hierro et al., 2004; Teo et al., 2004) , the NZF1 domain (Gill et al., 2007) , and the GLUE domain of the yeast complex (Teo et al., 2006) and the GLUE domain of the human complex (Alam et al., 2006; Hirano et al., 2006) . One essential component was lacking to model the complete ESCRT-II structure: the structure of the predicted helical regions in the Vps22 N terminus and in Vps36 between the GLUE and WH domains. We have now found that the most N-terminal predicted helix of the core of each subunit (H0) is flexibly attached to the core assembly. We have been able to assign functions to each of these two regions. The VPS22-H0 participates in membrane binding, while the VPS36-H0 interacts with ESCRT-I. The most significant finding from the crystallographic analysis is that ESCRT-II contains a helical domain composed of portions of both the VPS22 and VPS36 subunits. As described below, this domain appears to serve as a structural platform for the GLUE domain.
While ESCRT-II is too small to yield a cryo-EM reconstruction, we have been able to use hydrodynamic analysis (Garcia de la Torre et al., 2000; Kostelansky et al., 2007) together with the ESCRT-II core structure and the previously determined structure of the GLUE domain (Alam et al., 2006; Hirano et al., 2006) to model the conformation of the complete human complex in solution. This analysis shows unambiguously that human ESCRT-II has a compact conformation in solution. This is in sharp contrast to the ESCRT-I complex, where the functional domains extend away from the core on freely flexing linkers (Kostelansky et al., 2007) . The constraints imposed by known crystal structures and by experimental hydrodynamic data indicate that the GLUE domain must directly contact the helical domain. Thus, one function of the helical domain appears to be to scaffold the GLUE domain in the closed conformation of ESCRT-II.
Current models of ESCRT function invoke either the sequential or cooperative assembly of multiple ESCRT complexes on the endosomal membrane (Hurley, 2008; Nickerson et al., 2007; Saksena et al., 2007; Williams and Urbe, 2007) . The yeast ESCRT-I and -II complexes assemble together through a required interaction between the ESCRT-I Vps28-CTD and the ESCRT-II Vps36 NZF1 domain (Gill et al., 2007) , although the existence of additional interactions has not been ruled out. Indeed, we find that the yeast ESCRT-I/II supercomplex is compact in solution (M.S. Kostelansky and J.H.H., unpublished data), consistent with the presence of more than one interaction site. Human ESCRT-II lacks an NZF domain, and the available evidence that it interacts directly with human ESCRT-I has been limited to two-hybrid studies of isolated subunits (Langelier et al., 2006) . Here, we find that human ESCRT-II interacts robustly with the human VPS28-CTD. A motif within the ESCRT-II VPS36-H0 is necessary but not sufficient for this interaction. This motif is conserved in yeast Vps36, consistent with the possibility that the yeast ESCRT-I/II interaction involves more than one point of contact. The observation that the motif is necessary but not sufficient for the interaction suggests to us that ESCRT-I recognition by ESCRT-II involves an extended epitope.
Based on the highly dynamic nature of the ESCRT-II HD region and the observation of a dramatic solubility change upon mixing ESCRT-II and the ESCRT-I VPS28-CTD, we speculate that formation of the ESCRT I/II supercomplex entails a large conformational change. A similar solubility change was observed when yeast ESCRT-II or its Vps25 subunit was mixed with the yeast ESCRT-III subunit Vps20 (Teo et al., 2004 ). It will be interesting to assess whether there are widespread conformational changes when ESCRTs assemble with one another and with membranes. Such changes could have important implications for the membraneremodeling interactions that are catalyzed by the ESCRT system.
The mechanism of membrane targeting by ESCRT-II has attracted considerable attention. ESCRT-II is functionally activated by ESCRT-I. However, ESCRT-I is not required for the recruitment of ESCRT-II, since the loss of ESCRT-I can be rescued by the overexpression of ESCRT-II subunits (Babst et al., 2002) . Yeast ESCRT-II binds with moderate-to-high affinity to PIP-containing liposomes in the absence of ESCRT-I (Kostelansky et al., 2007; Teo et al., 2004 Teo et al., , 2006 . The principal site for PIP binding was first localized to the GLUE domain in studies of human ESCRT-II by Stenmark and colleagues (Slagsvold et al., 2005) . This study showed that the human ESCRT-II GLUE domain bound in vitro to immobilized PI(3,4,5)P 3 in a dot-blot format and, to a lesser extent, to PI(3,4)P 2 and PI(3,5)P 2 (Slagsvold et al., 2005) . PI(3,4,5)P 3 is typically present at the plasma membrane of cells stimulated by hormones such as insulin and PDGF, but is not characteristic of endosomal membranes. The GLUE domain of yeast ESCRT-II, in contrast, bound preferentially to PI(3)P when presented in liposomes, and the isolated yeast GLUE domain targets to endosomes when expressed in cultured human cells (Teo et al., 2006) . Here, we deduce, based on comparison of the intact and GLUE-domain deleted ESCRT-II complexes, that the human ESCRT-II GLUE domain binds to a variety of phosphoinositides. Deletion of the GLUE domain sharply reduces binding to the endosomal lipids PI(3)P and PI(3,5)P 2 but more modestly reduces binding to PI(3,4,5)P 3 . Deleting Vps22-H0 has a modest effect on binding to PI(3)P and most other PIPs compared to the GLUE domain deletion. However, the Vps22-H0 deletion reduces binding to PI(3,5)P 2 and PI(3,4,5)P 3 by about the same extent as the GLUE domain deletion. We infer there is a strong electrostatic interaction between Vps22-H0 and the polyanionic PI(3,5)P 2 and PI(3,4,5)P 3 . The ability of human ESCRT-II to bind to PI(3)P and PI(3,5)P 2 is consistent with the endosomal function of ESCRT-II. The binding to PI(3,4,5)P 3 and other nonendosomal PIPs is consistent with the previous report of a GLUE-PI(3,4,5) P 3 interaction (Slagsvold et al., 2005 ) but hard to rationalize in terms of the endosomal role of ESCRT-II. The GLUE domain of Drosophila ESCRT-II, which more closely resembles human as opposed to yeast ESCRT-II, binds to bicoid mRNA (Irion and St Johnston, 2007) . Thus, the propensity of human ESCRT-II to bind highly acidic lipids may reflect this or other nonendosomal functions (Slagsvold et al., 2006 ) that involve binding to various highly acidic ligands.
The observation that both the Vps36 GLUE domain and the Vps22 H0 contribute to lipid binding in vitro suggested to us that a combinatorial mechanism evolved to drive high-affinity membrane targeting of ESCRT-II ( Figure 6 ). Multivalent membrane targeting is widely used in the ESCRT system and other trafficking pathways for signal integration and coincidence detection. Given that ESCRT-I is involved in the functional activation of ESCRT-II, it is intriguing that ESCRT-I binds to a region of ESCRT-II very close to the locus of membrane binding and that this interaction appears to trigger a structural change. In conclusion, we have derived here a structural and conceptual framework for a more precise mechanistic understanding of the interplay between ESCRT-I and membrane binding by ESCRT-II. More importantly, the organization of ESCRT-II deduced here, together with similar models for the overall structures of the Vps27-Hse1 (Prag et al., 2007) and ESCRT-I (Kostelansky et al., 2007) complexes, will underpin higher order structural studies of the ESCRT system.
EXPERIMENTAL PROCEDURES Protein Expression and Purification
Full-length genes for human VPS22, VPS25, and VPS36 were synthesized by PCR-based gene synthesis. Oligonucleotides were designed by the program DNAWorks (Hoover and Lubkowski, 2002) . The nucleotide sequences of the genes were optimized for expression in E. coli, and restriction enzyme recognition sequences in the multiple cloning sites of pST39 vector were removed from the genes for efficient cloning of multiple genes into the vector. VPS22 was tagged with an N-terminal hexahistidine and a TEV protease cleavage site. The plasmid was transformed into E. coli strain BL21(DE3) Star and expressed overnight at 30 C. Cells were resuspended in buffer (2X PBS plus 20 mM imidazole) and lysed by sonication. The ESCRT-II complex was isolated using Ni 2+ affinity chromatography. The eluate was concentrated and the histidine tag was removed with TEV protease. The ESCRT-II complex was further purified by a Superdex S200 size exclusion chromatography.
The fractions containing the complex were concentrated in buffer 10 mM Tris-HCl (pH 8.0), 100 mM NaCl.
Crystallization Form I crystals of construct g ( Figure 3C ) were grown by vapor-diffusion methods at 25 C over a reservoir of 100 mM Na-Acetate (pH 4.5), 5% PEG 4000, 15% glycerol for 1 week. Crystals were cryoprotected in reservoir solution supplemented with 20% (v/v) glycerol and flash frozen under N 2 gas at 95 K. Heavy atom derivative crystals were prepared by cocrystallization or by soaking crystals in heavy atom solutions. Form II crystals of construct a ( Figure 3C ) were obtained in 100 mM Tris-HCl (pH 8.5), 40% PEG300 using a microseeding technique.
Crystallographic Analysis
Native data for the form I crystal VPS36 GLUE domain and VPS22 H0 truncation (construct g, Figure 3 ) were collected to 2.6 Å resolution from a single frozen crystal with an MAR CCD detector at beamline 22-ID, APS. The data sets were anisotropic with weak diffraction along c extending only to 2.9 Å resolution. All data were processed and scaled using HKL2000 (HKL Research). Heavy atom derivative data sets were collected with an R-AXIS IV image-plate system attached to a Rigaku rotating-anode generator providing Cu K a radiation. MIR phasing was carried out using the program SOLVE (Terwilliger and Berendzen, 1999 ) at 3.6 Å resolution (Table 1) , and the phases were further improved by RESOLVE (Terwilliger, 2000) . The initial model was built manually into the density-modified map using the programs O (Jones et al., 1991) and Coot (Emsley and Cowtan, 2004) . Tracing of the backbones was facilitated by comparing the homologous structure of yeast ESCRT-II complex; then the density map was improved using model phase combination and the resolution was extended to 2.6 Å resolution. The refinement was carried out using CNS (Brunger et al., 1998) and Refmac (CCP4, 1994). The final model for form I consisted of residues 172-385 from VPS36, residues 34-252 from VPS22, and residues 4-176 and 5-101 from VPS25. There are 97.2% of the residues in the most favored and additional allowed regions of the Ramachandran plot. Seven residues have conformations in disallowed regions, and all of these are located in regions of high mobility at the extreme termini of chains, in the helical domain, or in the flexible VPS25 WH2 domain. The structure of the form II crystal (construct a, Figure 3 ) was determined by molecular replacement with the program MOLREP using the form I structure as a starting model. Residues 149-169 from VPS36 and residues 1-25 from VPS22 are present in construct a, but could not be visualized in electron density and are presumed to be disordered. All structural figures were prepared using the program PyMOL (W. Delano, http://pymol.sourceforge.net/).
Hydrodynamic Modeling
Residues in the N and C termini of the subunits (residues 1-3 in VPS25, 27-33 and 253-258 in VPS22) that were present in the crystallized construct of form I but missing in the electron density were modeled as random coils, and the random coil conformation was adjusted iteratively with interactive graphics until the calculated and experimental R H values were in agreement within < 0.1 nm ( Figure 3A ). Essentially the same procedure was used to place VPS22-H0 and VPS36-H0, which were modeled as helices on the basis of secondary structure prediction, using the crystal structure of form II and the corresponding R H value ( Figure 3A ). Full-length ESCRT-II was modeled by positioning the GLUE domain interactively so as to obtain agreement with between the calculated and experimental R H values ( Figure 3A ). The structure of the human ESCRT-II GLUE domain was obtained from PDB entry 2HTH (Alam et al., 2006) .
Pull-Down Assays
For GST-pull-downs, 50 ml gluthathione sepharose resin was prewashed with binding buffer (1X PBS). GST-tagged human VPC28 C-terminal domain (residues 123-220) was bound to the resin. Various purified constructs of human ESCRT-II complex were mixed with the GST-VPS28 CTD-bound resin for 30 min at room temperature. GST-bound resin was used as a negative control. The beads were then washed three times with 1X PBS. and the bound proteins were analyzed by SDS-PAGE.
Liposome-Binding Experiments
The synthetic lipids used in this study were all purchased from Avanti Polar Lipids except for PI(3)P, which was purchased from Echelon. All liposomes contain 0.5% of a dye, lissamine rhodamine B, for quantitation of the liposomes. The liposomes were prepared at a total lipid concentration of 1 mg/ml by evaporating the solvent from the desired lipid mixture using a nitrogen stream. The dried lipids were resuspended in 150 ml 0.3 M sucrose, and the solution was incubated at room temperature under nitrogen for 1 hr with periodic vortexing; 1 ml water was added and the sample was sedimented in an ultracentrifuge at 128,000 3 g for 30 min at 4 C. The supernatant was removed, and the pellet was frozen and thawed three times in liquid nitrogen. The pellet was dissolved in 1 ml buffer A (20 mM HEPES [pH 7.4] and 150 mM NaCl) and extruded 10 times through a 0.1 mm filter. For binding experiments, 100 mg liposomes were mixed with 80 mg protein and were brought up to a total volume of 200 ml with buffer A, incubated at room temperature for 30 min, and sedimented at 128,000 3 g at 4 C for 30 min. The pellet was washed once with 200 ml buffer A and again sedimented for 30 min. Samples of the supernatant (10 ml) and pellet were analyzed by SDS-PAGE. The intensities of bands in the SDS-PAGE gels were measured using the LabWorks 5.6 program (UVP).
Plasmid Construction and Yeast Strains
The vps22D vps36D strain was prepared by replacing the VPS36 gene with a nourseothrisin resistance gene from a vps22D strain by homologous recombination. The vps4D vps22D vps36D strain was made by homologous recombination between the VPS4 and URA3 genes in the vps22D vps36D strain. The complete expression cassette of Vps22 and the open reading frame of Vps36 were amplified from yeast genomic DNA and cloned into YCplac111 and pRS413MET25 vectors, respectively. The N-teminal 30 amino acid deletion of Vps22 and the R89A and R261A mutations of Vps36 were introduced by Quickchange mutagenesis (Stratagene). DNA coding for green fluorescent protein (GFP) was fused to the 3 0 end of the vps22 cassette using PCR, and the PCR product was cloned to the YCplac111 vector. Plasmids encoding VPS22 and VPS36 genes, and the pGO45 vector, were transformed to wildtype and mutant strains. The following yeast strains were used: BY4741 (MATa his3D1 leu2D0 met15D0 ura3D0 
Microscopy
Yeast strains expressing the appropriate alleles were harvested at an A660 of 0.4-0.6, labeled with FM4-64 for vacuolar membrane staining (Vida and Emr, 1995) . Uptake of FM4-64 by live cells was performed at 30 C for 1 hr, after which cells were resuspended in selection media and incubated for 30 min at 30 C. Visualization of cells was performed on an LSM510 fluorescence microscope (Carl Zeiss MicroImaging) equipped with fluorescein isothiocyanate (FITC) and rhodamine filters and captured with a digital camera.
ACCESSION NUMBERS
Crystallographic coordinates have been deposited in the Protein Data Bank with accession codes 3CUQ for crystal form I and 2ZME for form II. 
SUMMARY
The multimeric membrane-tethering complexes TRAPPI and TRAPPII share seven subunits, of which four (Bet3p, Bet5p, Trs23p, and Trs31p) are minimally needed to activate the Rab GTPase Ypt1p in an event preceding membrane fusion. Here, we present the structure of a heteropentameric TRAPPI assembly complexed with Ypt1p. We propose that TRAPPI facilitates nucleotide exchange primarily by stabilizing the nucleotide-binding pocket of Ypt1p in an open, solvent-accessible form. Bet3p, Bet5p, and Trs23p interact directly with Ypt1p to stabilize this form, while the C terminus of Bet3p invades the pocket to participate in its remodeling. The Trs31p subunit does not interact directly with the GTPase but allosterically regulates the TRAPPI interface with Ypt1p. Our findings imply that TRAPPII activates Ypt1p by an identical mechanism. This view of a multimeric membrane-tethering assembly complexed with a Rab provides a framework for understanding events preceding membrane fusion at the molecular level.
INTRODUCTION
In eukaryotic cells, vesicles transport materials between membrane-bound compartments. After a vesicle buds from a donor membrane, it travels through the cytoplasm to its target membrane, where it fuses to deliver its cargo. This membrane-fusion event is mediated by SNAREs, a family of membrane proteins located on the vesicle and target membranes (Jahn and Scheller, 2006) . Vesicle transport, however, also requires the interplay of a large number of peripheral membrane proteins that act upstream of the SNAREs. These include coat proteins that are needed for cargo selection and vesicle budding, tethering proteins, and small GTPases of the Rab family involved in regulation. Tethers are either long coiled-coil proteins or large multimeric complexes that mediate the initial interaction of the vesicle and its target membrane (reviewed in Cai et al., 2007a) .
TRAPPI is one of the best-characterized multiprotein tethering complexes. First described in the yeast S. cerevisiae (Sacher et al., 1998) , TRAPPI subunits are present in all eukaryotes (Koumandou et al., 2007) . In yeast, TRAPPI mediates the tethering of endoplasmic reticulum (ER)-derived COPII-coated vesicles at the cis-Golgi (Sacher et al., 1998) . Tethering involves interactions between the TRAPPI subunit Bet3p and Sec23p (Cai et al., 2007b) , a component of the COPII coat adaptor complex (Kuehn et al., 1998) . This interaction targets a COPII vesicle to the Golgi (Cai et al., 2007b) . Critically, TRAPPI also functions as a guanine nucleotide exchange factor (GEF) for the Rab GTPase Ypt1p (Sacher et al., 2001) , facilitating the conversion of the inactive GDP-bound form of Ypt1p to the active GTPbound form. Membrane fusion proceeds only once Ypt1p is activated by TRAPPI (Cai et al., 2007a) . TRAPPI shares multiple subunits with the TRAPPII complex, which mediates trafficking events within the Golgi and from the early endosome to the late Golgi (Cai et al., 2005) .
The TRAPPI complex comprises seven small subunits (two copies of Bet3p and one copy each of Bet5p, Trs20p, Trs23p, Trs31p, and Trs33p), which range in size from 18 to 33 kDa, as well as a larger 80 kDa protein Trs85p (Sacher et al., 1998 . Except for Trs33p and Trs85p, all of the TRAPPI subunits are required for cell viability (Sacher et al., 1998 . Unusually, TRAPPI GEF activity does not reside on any one subunit (Kim et al., 2006; Cai et al., 2007b) but requires a minimal complex of Bet3p, Bet5p, Trs23p, and Trs31p (Kim et al., 2006) . The requirement of complex assembly as a prerequisite for GEF activity may allow for additional regulation of vesicle transport.
To understand how TRAPPI subunits cooperate in activating Ypt1p, we have determined the crystal structure of a TRAPPI subassembly in complex with Ypt1p at a resolution of 3.7 Å . The structure offers a snapshot of the interactions between a multimeric membrane-tethering complex and a Rab GTPase. The TRAPPI subcomplex studied contains the minimum number of subunits (two copies of Bet3p and one each of Bet5p, Trs23p, and Trs31p) needed to activate Ypt1p (Kim et al., 2006) , and in the structure, this assembly stabilizes the GTPase in its intermediate, nucleotide-free form. A comparison of nucleotide-free Ypt1p with existing nucleotide-bound structures of the enzyme (PDB ID 1YZN; Eathiraj et al., 2005) or its mammalian homolog Rab1a (PDB ID 2FOL) allows us to propose a mechanism for guanine nucleotide exchange in which each subunit in the TRAPPI subassembly contributes to the activity of this multimeric GEF.
RESULTS AND DISCUSSION

Overview of the TRAPPI Subcomplex
The crystal structure of a TRAPPI subassembly ( Figures 1A-1C ) consisting of one copy each of Bet5p, Trs23p, and Trs31p and two copies of Bet3p (named Bet3p-A and Bet3p-B) was determined in complex with a C-terminally truncated Ypt1p (residues 1-180). Data collection and refinement statistics are shown in Table S1 (see Supplemental Data available online). The 26 residue Ypt1p C terminus that was truncated is not required for activation of nucleotide exchange by TRAPPI (data not shown).
The TRAPPI subassembly is about 135 Å long and 30-75 Å in diameter ( Figure 1A) . One of its surfaces is largely acidic, whereas the other has both basic and acidic regions ( Figure 1B ). Bet3p-A, Bet5p, Trs23p, and Bet3p-B are arranged end to end along the length of the complex ( Figures 1A and 1C ). Bet3p-A/ Bet5p and Bet3p-B/Trs23p are related by a 2-fold rotation around an axis centered at the Bet5p/Trs23p interface. Trs31p binds at one end of the otherwise cylindrical complex, interacting with both Trs23p and Bet3p-B.
The yeast small TRAPPI subunits in the crystal structure have mixed a/b topologies ( Figure 1C ) similar to those previously described for their vertebrate homologs (Kim et al., 2006 (Kim et al., , 2005b Turnbull et al., 2005) . Despite limited sequence homology, Bet5p and Trs23p (20% sequence identity) share a common fold, as do Bet3p and Trs31p (15% sequence identity). The yeast Trs23p protein does not have the PDZ-like domain described for the mammalian protein, and insertions in the yeast proteins with respect to the mammalian sequences are for the most part disordered in the crystal structure. These insertions include residues 76-103 and 148-168 in Trs23p and residues 1-54 and 104-164 in Trs31p. Bet3p has an additional N-terminal a helix, which plays a role in subunit interactions. Importantly, the C-terminal residues of Bet3p, disordered in all existing structures of the mammalian homolog (Kim et al., 2005a (Kim et al., , 2005b Turnbull et al., 2005; Kummel et al., 2006b ; and in TRAPP subcomplexes as in Kim et al., 2006) , are ordered in the Ypt1p/TRAPPI complex, where they are involved in intermolecular contacts with Ypt1p.
A deep channel lined by hydrophobic residues traverses each of the Bet3p subunits. Bet3p is palmitoylated via a thioester linkage to a conserved cysteine (C80) (Turnbull et al., 2005) . We have modeled a palmitoylate group into the channel of Bet3p-A, where we find density continuous with Cys80 in averaged composite omit maps ( Figure S1 ). The bound fatty acid is less well defined in Bet3p-B, though there is electron density deep in the channel corresponding to eight to nine methylene groups of the hydrocarbon tail. The palmitoyl group has been shown to contribute to the stability of Bet3p (Kummel et al., 2006a) . Mutational analysis suggests, however, that neither the palmitoyl group (Kim et al., 2005a; Turnbull et al., 2005) nor the hydrophobic channel ( Figure S2 ) are essential for TRAPP function.
Ypt1p Interactions with TRAPPI
The Ypt1p binding site is on the acidic surface of the TRAPPI subassembly. The interface is formed primarily by the Trs23p subunit with smaller contributions from the two copies of Bet3p and Bet5p (see Figures 1A and 1B) . The total accessible surface buried in the interface between Ypt1p and TRAPPI is 2990 Å 2 . Accessible surfaces buried in the interfaces with Trs23p, Bet3p-A, Bet3p-B, and Bet5p measure $1870, $650, $250, and $250 Å 2 , respectively. There is no direct interaction between Ypt1p and Trs31p. TRAPPI interacts ( Figure 2 ) primarily with residues in the central b sheet of Ypt1p (in strands S1, S2, and S3), the switch I and II regions (residues 31-45 and 64-78), and the phosphate-binding loop, or P loop (residues 15-23). Switches I and II are those regions in the nucleotidebinding pocket that adopt different conformations in the active and inactive forms of Ypt1p, and the P loop is important in binding the b-and g-phosphates of nucleotides. Structures are available for Ypt1p in complex with the nonhydrolysable GTP analog guanosine-5 0 (b,g) imidotriphosphate (GppNHP) (PDB ID 1YZN; Eathiraj et al., 2005) and its mammalian homolog Rab1a bound to GDP (PDB ID 2FOL). Rab1a is nearly identical to Ypt1p over most of its sequence. In the Ypt1p/TRAPPI complex, the Ypt1p N terminus (residues 4-10, where 7-10 are in b strand S1) contacts Trs23p and has shifted with respect to nucleotide-bound forms (Figures 2 and 3) . Small shifts in adjacent structural elements, the loop between strands S2 and S3 (residues 53-54), as well as the C terminus (residues 150-174, including H5) accompany the change in the N terminus.
The most dramatic changes in Ypt1p, however, are in the nucleotide-binding pocket. Residues 150-155 in a loop at the Ypt1p C terminus form part of this pocket. In the Ypt1p/TRAPPI complex, they are shifted into the pocket close to the position occupied by the guanosine base in nucleotide-bound structures. The Ala152 Cb would be within 2 Å of atoms in the guanosine base, in a position incompatible with nucleotide binding.
The nucleotide-binding pocket is further perturbed by the insertion of the Bet3p-A C terminus, which would clash sterically (particularly at residues 189-193) with switch I as oriented in nucleotide-bound forms of Ypt1p/Rab1a (Figures 3A and 3B) . The switch I region (residues 27-45) of Ypt1p is rearranged relative to its nucleotide-bound conformations ( Figures 3A and 3B) , opening up the nucleotide-binding pocket. In their new conformation, switch I residues 37-45 contact the Bet3-A C terminus as well as residues in helix H1 of Bet5p and helix H1 of Trs23p (Figure 2) . Residues 32-36 in the middle of switch I are not well ordered in the complex structure. In the nucleotide-bound form, the highly conserved Tyr33 from this sequence contacts the guanine base via an edge-to-face aromatic interaction (Eathiraj et al., 2005; PDB IDs 1YZN, 2FOL) . Mutating this residue to alanine (Y33A) accelerates GDP release by $10-fold ( Figure 3C ) while not affecting nucleotide uptake ( Figure 3D ), thereby lowering Ypt1p affinity for GDP by an order of magnitude. Thus, the perturbation of Tyr33 during switch I reorganization would similarly be expected to weaken the affinity for GDP in the TRAPPI-bound form of Ypt1p and accelerate GDP release by roughly an order of magnitude.
The switch II region of the nucleotide-binding pocket also alters its conformation in the Ypt1p/TRAPPI complex. Switch II residues are disordered in the Rab1a/GDP structure (PDB ID 2FOL), and their conformation differs in the active and TRAPPIbound forms of Ypt1p ( Figures 3A and 3B ). In the Ypt1p/TRAPPI complex, switch II is folded against a surface formed by helices H1 of Trs23p, H1 of Bet5p, and residues near the C terminus of Bet3p-B of TRAPPI. This interaction drives the formation of a helix (H2; Figures 2, 3A , and 3B) and moves switch II residues out of the nucleotide-binding pocket as compared with their position in activated Ypt1p. We will discuss the implications of switch II folding below. The conformation of the P loop in TRAPPI-bound Ypt1p is similar to that of nucleotide-bound forms of Ypt1p and Rab1a. In the Ypt1p/TRAPPI complex, the loop is stabilized in part by a hydrogen-bonding interaction between the P loop residue Lys21 and Glu192 in the Bet3p-A C terminus ( Figures 3A and  3B ). As modeled, this glutamate side chain (including Cb and Cg as well as the carboxylate group) would be within 1.6 Å of the nucleotide phosphates in the nucleotide-bound forms of Ypt1/ Rab1a, in a position incompatible with nucleotide binding. However, the sequence identity of residue 192 is not critical for nucleotide exchange, as the E192A/D193A double mutation in the Bet3p C terminus has only a small effect on GEF efficiency (Table 1 and Figure 4A ).
TRAPPI Mutants with Impaired GEF Activity
Our structural studies suggest that the Bet3p-A C terminus, which is inserted into the Ypt1p nucleotide-binding site, may play an important role in guanine nucleotide exchange. The C terminus may be important for initiating the conformational changes in switch I that help to catalyze nucleotide exchange. Additionally, contacts with the Bet3p C terminus seen in the structure (Figure 2 ) may be important for stabilizing switch I in its new conformation. To assess the importance of the Bet3p C terminus for exchange, we prepared TRAPPI subassemblies that incorporate C-terminally truncated versions of Bet3p. Constructs of Bet3p that contained 185, 188, or 191 residues of the 193 amino acid sequence catalyzed nucleotide exchange at least 150-fold less efficiently than the TRAPPI complex with full-length Bet3p (Table 1 and Figures 4A and 4B ), consistent with a critical role for the entire Bet3p C terminus in the exchange mechanism.
Mutations in other TRAPPI surfaces at the Ypt1p interface would also be expected to affect Ypt1p recognition and possibly nucleotide exchange. Indeed, we were able to entirely, or almost entirely, eliminate TRAPPI GEF activity by mutating surface patches on any one of three different subunits: Bet3p, Bet5p, or Trs23p (Table 1 and Figures 4B and 4D) . We found that mutations in the Trs23p surface that interacts with strand S1 in the Ypt1p N terminus (S12K/G14M/L34K and M200A/P201W/ R203S) abrogate GEF activity entirely (Table 1 and Figure 4B) . Similarly, mutations designed to interfere with a switch I interaction, a double mutation in Bet5p (G46W/S50K), or a point mutation in Trs23p (S38R) completely inactivated TRAPPI (Table 1 and Figure 4B ). Finally, a quadruple mutation in Trs23p (H41A/G42M/A45W/I46R) at the switch II binding surface of TRAPPI reduced the catalytic efficiency to residual levels (Table 1 and Figure 4B ).
In addition to assessing the consequences of each of these mutations in vitro, we also examined their effect on viability in yeast. Two different methods were used to construct the mutants. The C-terminal truncations of Bet3p were constructed using the method of Longtine et al. (1998) . For the other mutations, a mutant copy of each gene was constructed by sitedirected mutagenesis on a CEN plasmid (LEU2) and then transformed into a strain in which the sole copy of the wildtype gene was on a CEN balancing plasmid (URA3). The balancing plasmid with the wild-type gene was subsequently lost on a 5-fluoroorotic acid (5-FOA) plate, allowing us to evaluate the effect of the mutation on growth. We found that TRAPP mutants lacking all GEF activity in vitro were inviable (Table 1 and Figure 4C ). However, mutants with residual in vitro activity grew as well as wild-type at 25 C or 37 C and did not display defects in invertase secretion (Table 1 and Figures 4C and S3) . A likely explanation for this apparent anomaly is that TRAPPI may act more effectively in the cell than in vitro. Soluble TRAPPI and Ypt1p were used in vitro, whereas in cells, Ypt1p is anchored to a membrane via its prenylated C terminus, and exchange occurs at the membrane. Thus, the effect of certain mutations may be less pronounced in vivo than in vitro.
Mechanism for Ypt1p Activation
Biochemical solution studies of nucleotide binding and exchange reveal the kinetic basis of Ypt1p activation by TRAPPI. TRAPPI accelerates the dissociation of Ypt1p-bound GDP (k -GDP ) >400-fold (Table 1 and Figure 4A ). The initial velocities of TRAPPI-dependent nucleotide exchange (Table 1 and Figure 4A ) yield apparent second-order rate constants for TRAPPI activation of nucleotide exchange from Ypt1p (equivalent to the enzymatic k cat /K m ) and serve as a practical reference with which to assess the catalytic efficiency of a GEF (Itzen et al., 2007) . The catalytic efficiency of TRAPPI, .016 ± .001 mM À1 s À1 , is intermediate between two other characterized Rab GEFs, Vps9 and Sec2p (Esters et al., 2001; Itzen et al., 2007) . In addition, TRAPPI accelerates GTP binding to Ypt1p (k +GTP ) $30-fold ( Figure 4E ), more than has been observed for other Rab GEFs (Esters et al., 2001; Itzen et al., 2007) but comparable to non-Rab GEFs (Klebe et al., 1995) . The acceleration of nucleotide dissociation and binding serves as a framework for formulating structure-based models of TRAPPI-mediated nucleotide exchange from Ypt1p.
The structure and kinetic analysis of TRAPPI mutants (Table 1  and Figure 4) suggest an important role for the Bet3p-A C terminus in the guanine nucleotide-exchange mechanism. In the structure, which represents an intermediate in exchange following release of bound nucleotide, the Bet3p-A C terminus invades the GTPase nucleotide-binding pocket. We propose that the Bet3p-A C terminus functions in the remodeling of switch I that promotes the release of bound nucleotide. Conformational changes in switch I open the nucleotide-binding pocket and, in effect, uncage bound nucleotide to facilitate GDP release. Additionally, switch I remodeling removes Tyr33, which stabilizes bound nucleotide (Eathiraj et al., 2005) , from the binding site. This likely also plays a role in accelerating GDP release. Based on our kinetic analysis of the Ypt1p Y33A mutant, however, we would expect at most a 10-fold increase in GDP release with loss of the Tyr33 contact. The >400-fold acceleration in GDP release effected by TRAPPI must also result from other factors, such as the opening of the nucleotide-binding pocket discussed above. The Tyr33 perturbation does, however, help to explain the lower affinity of the TRAPPI-bound form of Ypt1p for GDP, which is an order of magnitude weaker than that of Ypt1p (unpublished data). The shift of the Ypt1p 150 s loop (residues 150-155) into a site close to that normally occupied by the guanosine base, which is induced by interactions with TRAPPI, may also weaken the affinity of Ypt1p for nucleotide. The final step of the nucleotide exchange reaction involves GTP uptake, which is accelerated by TRAPPI ( Figure 4E ). Holding switch I in an open conformation, which makes the pocket more solvent accessible, likely accounts at least partly for this acceleration. The folding of switch II, which adopts similar conformations in the Ypt1p/ TRAPPI complex and the GTP-bound form of Ypt1p ( Figures  3A and 3B) , would also contribute to faster GTP association with the TRAPPI-bound form of the GTPase. Elements of TRAPP, particularly the Bet3p-A C terminus, occupy a part of the nucleotide-binding pocket in the complex with Ypt1p. Any decrease in the rate of GTP binding that results from the need for these elements to exit the binding site must be more than compensated for by the favorable conformations of switches I and II.
All known GEFs reconfigure the nucleotide-binding pocket, often opening it by rearranging the switch regions (reviewed in Bos et al., 2007) . Many GEFs facilitate this rearrangement by inserting a protein ''wedge'' into either the magnesium or the nucleotide-binding site (Bos et al., 2007) . With TRAPPI, the C-terminal end of Bet3p-A may be functionally equivalent to a wedge, Figure S6A ). The concentration dependence of k obs for Ypt1p (black) and Ypt1-p(Y33A) (green) is shown. The second-order association rate constants for GDP binding (k +GDP ) determined from the slopes of the best fits to the data over this range are 0.05 ± 0.01 mM À1 s À1 for Ypt1p and 0.07 ± 0.01 mM À1 s À1 for Ypt1p(Y33A).
though it differs mechanistically in that it is not a rigid structural element and may be poorly ordered in the absence of Ypt1p. TRAPPI is similar to GEFs for Ras and several of the Rab GTPases (Boriack-Sjodin et al., 1998; Delprato and Lambright, 2007; Dong et al., 2007; Sato et al., 2007) in that the guanine nucleotide-exchange mechanism involves the displacement of a conserved aromatic residue required for nucleotide stabilization. In Ypt1p, this aromatic side chain is Tyr33. TRAPPI differs most strikingly from other GEFs in that its exchange activity is linked to the assembly of a multimeric subcomplex. Our structure delineates a role for each of the subcomplex proteins in nucleotide exchange. TRAPPI provides a surface against which regions of Ypt1p are reorganized into their nucleotide-free conformation. Most of this surface is formed by the Trs23p subunit, but smaller contributions from Bet3p (A and B) and Bet5p are also important (Figure 2 ). Indeed, we have shown that mutations in the surfaces of any of the three proteins can interfere with TRAPPI GEF activity (Table 1 and Figure 4) . Additionally, Bet5p has a major structural role both as a linker between Trs23p and Bet3p-A and in directing the Bet3p-A C-terminal residues toward the Ypt1p nucleotide-binding pocket. The C terminus of Bet3p-A, which perturbs the nucleotide-binding pocket in the Ypt1p/TRAPP complex, enhances the efficiency of guanosine nucleotide exchange.
Trs31p does not interact directly with Ypt1p, and yet a TRAPPI subcomplex lacking Trs31p does not activate Ypt1p (Kim et al., 2006) . Comparison of our structure with those of the vertebrate complexes Trs20/Bet3-B/Trs31 and Trs23/Bet5/Bet3-A/Trs33 (PDB IDs 2J3W, 2J3T; Kim et al., 2006) , neither of which has GEF activity (Kim et al., 2006; Cai et al., 2007b) , suggests that Trs31p promotes GEF activity by affecting the conformation of Trs23p at the Ypt1p-binding interface. Bet3p-B/Trs31p and Trs23p/Bet5p/Bet3p-A subcomplexes from yeast and vertebrates superimpose well (rmsd values of just 1.8 Å on 317 equivalent Ca positions and 2.4 Å on 414 equivalent Ca positions, respectively). However, the structures differ significantly at the three-way interface between Trs23p, Trs31p, and Bet3p-B ( Figure 5 ). The formation of this TRAPPI interface, which is not present in either of the vertebrate complex structures, causes complementary shifts in elements of Trs31p and Trs23p. In particular, the connecting loop between strand S2 and helix H4 of Trs31p moves toward Trs23p, and helices H2 and H3 of Trs23p with their connecting loop shift by up to 12 Å to accommodate the new position of the Trs31p loop. The shifted connecting loop in Trs23p interacts with Ypt1p (strand S1) in the Ypt1p/TRAPPI complex (see Figure 2) , and this interaction is important for GEF activity because mutations in the loop (M200A/P201W/R203S) abolish GEF function (Table 1 and Figure 4B ). Thus, binding of the GTPase may depend on conformational changes resulting from the formation of the Trs23p/Trs31p/Bet3p-B interface. Alternatively, the formation of the three-way interface may stabilize conformational changes that only occur upon Ypt1p binding. The importance of the Trs23p/Trs31p/Bet3p-B interface for GEF activity is supported by the finding that a double mutation in Trs23p (T136E/Y183D) at this interface abolishes TRAPPI activation of Ypt1p (Kim et al., 2006) . In summary, Bet3p, Bet5p, and Trs23p are essential for Ypt1p binding, with the C terminus of Bet3p-A playing a critical catalytic role in the exchange mechanism. Bet5p is necessary for the assembly of the GEF core; and Trs31p, and likely Bet3p-B, appears to function allosterically by affecting the conformation of Trs23p.
TRAPPII Is Also a Ypt1p Exchange Factor
To date, ten different TRAPP subunits have been identified . TRAPPI and TRAPPII share seven of these subunits, while three subunits (Trs65p, Trs120p, and Trs130p) are unique to the larger TRAPPII complex (Sacher et al., 2001) . The observation that TRAPPII contains all of the subunits that are essential for Ypt1p activation prompted us to determine whether TRAPPII is also a Ypt1p GEF. To isolate fully assembled TRAPPI and TRAPPII complexes, we used a yeast strain in which Protein A-tagged Bet3p replaced the endogenous protein. The tag we used has no appreciable effect on the assembly of the TRAPP complexes (Cai et al., 2005) or on Ypt1p activation (Wang et al., 2000) . Lysate prepared from this strain was sieved on a Superdex-200 column to separate TRAPPI and TRAPPII, as described previously (Sacher et al., 2001 ). Fractions containing Table 1 lists TRAPPI concentrations. Solid lines are the best fits to single exponentials yielding the observed GDP dissociation rate constant (k -GDP,obs ).
(C) Yeast cells harboring mutations in bet5 and trs23, which reduce GEF activity in vitro, were grown at 25 C on 5-FOA plates. All these mutants were inviable, except for trs23 (H41A/ G42M/A45W/I46R), which also grows at 37 C (data not shown). Yeast cells harboring C-terminal truncations in bet3, which reduce GEF activity in vitro, were grown at 25 C and 37 C on YPD plates. The 37 C plate is shown. The bet3 truncation mutants were viable. (D) TRAPPI oriented as in Figure 1A on the left. Residues that were mutated are indicated. Green, cyan, 46, 50 in Bet5p; orange, 12, 14, 34 in Trs23p; purple, [200] [201] 203 in Trs23p; yellow, 38 in Trs23p; indigo, [41] [42] [45] [46] (E) TRAPPI-bound Ypt1p associates with GTP $30 times faster than Ypt1p alone. MantGTP binding to nucleotide-free Ypt1p or Ypt1p/TRAPPI complex was monitored by fluorescence ( Figure S6B ). MantGTP concentration dependence of k obs for Ypt1p (black) and Ypt1p/TRAPPI complex (red) is shown. The second-order association rate constants for mantGTP binding (k +GTP ) determined from the slopes of the best fits of the data are 0.10 ± 0.01 mM À1 s À1 for Ypt1p and
either complex were then incubated with IgG Sepharose beads and washed. An analysis of the subunits present showed that both Trs33p and Trs130p were on the TRAPPII-containing beads, while TRAPPI-coated beads contained only Trs33p (data not shown). We found that TRAPPII potently stimulates nucleotide exchange on Ypt1p ( Figure 6A ). Furthermore, when we normalized guanine nucleotide exchange activity to the amount of Trs33p present in each fraction, TRAPPII and TRAPPI had comparable activity ( Figure 6A ). As would be expected for a Ypt1p GEF, TRAPPII binds to both nucleotide-bound forms of the GTPase and preferentially to the GDP-bound form ( Figure 6B ). Our results differ from earlier studies that suggested that TRAPPII is not an exchange factor for Ypt1p (Morozova et al., 2006) . In that study, TRAPP complexes were isolated from a strain overexpressing GST-tagged Bet5p, and one explanation is that the GST tag on Bet5p may have interfered with Ypt1p activation. The same study suggested that the addition of TRAPPII-specific subunits converts TRAPPI into a GEF for Ypt31p and its functionally redundant homolog Ypt32p (Morozova et al., 2006 ; also Jones et al., 2000), but we have been unable to repeat these results with our TRAPPII preparations ( Figures 6C  and 6D ). We have also found that a mixture of TRAPP complexes, isolated using TAP-tagged Trs33p, did not activate Ypt32p efficiently (Wang and Ferro-Novick, 2002) . The result that TRAPPII does not efficiently stimulate exchange for Ypt31p/Ypt32p is consistent with a previous report showing that depletion of TRAPPI and TRAPPII from yeast lysates eliminates Ypt1p GEF activity without affecting GEF activity on Ypt32p (Wang and Ferro-Novick, 2002) . Also consistent with the finding that TRAPPII is not a GEF for Ypt31p/ Ypt32p, we are unable to detect an interaction between TRAPPII and Ypt31p-GDP in vitro (data not shown). Thus, we conclude that TRAPPII is an exchange factor for Ypt1p and unlikely to be the exchange factor for Ypt31p/Ypt32p in vivo.
In addition to acting in ER-Golgi traffic, Ypt1p also functions at the late Golgi (A.S. and S.F.-N., unpublished data; Cai et al., 2007a) . In this respect, it differs from its mammalian homolog Rab1, which only mediates membrane transport between the ER and Golgi (Moyer et al., 2001) . Our data indicate that TRAPPII is the Ypt1p GEF that functions at the late Golgi. Importantly, the finding that TRAPPII is a Ypt1p GEF implies that the Ypt1p-binding site that we identified for TRAPPI remains accessible in TRAPPII. We conclude that TRAPPI and TRAPPII almost certainly activate Ypt1p by an identical mechanism.
TRAPP Tethering
The superposition, described here, of the two vertebrate subcomplexes Trs20/Bet3-B/Trs31 and Bet3-A/Bet5/Bet3-A/Trs23/Trs33 with yeast Bet3p-A/Bet5p/Trs23p/Bet3p-B/ Trs31p gives a model of the intact TRAPPI complex ( Figure 5A ). In the larger assembly, Trs20 interacts with Bet3-B/Trs31 and Trs33 interacts with Bet3-A/Bet5. The model is in agreement with a model proposed on the basis of the vertebrate subcomplexes and an $30 Å single particle reconstruction of yeast TRAPPI (Kim et al., 2006) .
The symmetry of TRAPPI suggests a mechanism by which this complex mediates vesicle tethering. It is known that Bet3p interacts with the Sec23p subunit of the COPII vesicle coat (Cai et al., 2007b) . In mammals, it has been demonstrated that the TRAPP complex mediates homotypic tethering between two COPIIcoated vesicles (Yu et al., 2006) . We therefore speculate that TRAPP interacts similarly with both vesicles via the two copies of Bet3 (see also Cai et al., 2007b) located at either end of the core complex as shown in Figure 5B . Bet3-A and Bet3-B would interact with the COPII subunit Sec23 using the same surfaces because of symmetry present in the TRAPP complex. Equivalent surfaces on Bet3-A and Bet3-B are accessible to both vesicles only if TRAPP is oriented as shown, because in any other orientation, binding by only one vesicle would block access to both of the equivalent Bet3 surfaces. In yeast, the architecture of the secretory pathway differs, and TRAPPI mediates heterotypic tethering of a COPII vesicle with the Golgi. Thus, in yeast cells, TRAPPI must have the ability to bind a Golgi receptor as well as Sec23p, but we speculate that the arrangement of the tethering complex with respect to membranes is similar to that of homotypic fusion. This model is consistent with a scenario in which TRAPPI first tethers the secretory vesicle to the Golgi membrane and then, with the Ypt1p-binding site still accessible, binds and activates the Rab protein. Our model differs from one previously proposed (Kim et al., 2006) , which would predict that in homotypic fusion, vesicles would interact with TRAPP in two different ways. (Mutational studies presented in Figure S4 show that data previously cited to support this other model are incorrect.)
Our recent observation that Ypt1p regulates both ER-Golgi transport and traffic between the early endosome and late Golgi (A.S. and S.F.-N., unpublished data) implies that Ypt1p is activated by one or more GEFs at distinct membrane-trafficking events. Accordingly, we have shown that TRAPPI, which functions in ER-Golgi traffic, and TRAPPII, which mediates trafficking events within the Golgi and at the late Golgi (Cai et al., 2005) , both activate Ypt1p. Presumably, TRAPPI and TRAPPII activate Ypt1p by the same mechanism using subunits shared by both complexes. The TRAPP complexes also function as tethers, however, that tether different membranes. TRAPPI, but not TRAPPII, binds to COPII-coated vesicles in vitro (Sacher et al., 2001) , whereas TRAPPII has been implicated in tethering COPI-coated vesicles (Cai et al., 2005) . Thus, the addition of TRAPPII-specific subunits (Trs65p, Trs120p, and Trs130p) must convert TRAPPI from a tether that mediates interactions between the COPII coat and early Golgi to one that functions in recognition between the COPI coat and late Golgi. Such a conversion implies that the TRAPPII-specific subunits not only mediate these new interactions but also mask binding sites on TRAPPI that would allow for interactions with the COPII coat and early Golgi.
Concluding Remarks
A formidable obstacle in understanding membrane traffic has been the limited knowledge regarding the interactions between the many proteins that coordinate these events. In this work, we have visualized the five proteins of the GEF core of TRAPP as they cooperate to activate Ypt1p. We propose that interactions with four proteins (Bet3p-A, Bet3p-B, Bet5p, and Trs23) in the complex stabilize Ypt1p in an open conformation facilitating nucleotide exchange. The Trs31p subunit does not interact directly with Ypt1p but regulates the conformation of Trs23p at the Ypt1p interaction surface.
EXPERIMENTAL PROCEDURES
Cloning Strategies and Protocols Used for Constructing the bet3, bet5, and trs23 Mutants Details are in the Supplemental Data.
Overexpression and Purification
We prepared several TRAPPI subcomplexes. We were able to obtain crystals only with a complex containing Bet3p, Bet5p, Trs23p, and Trs31p but not additional TRAPPI subunits (Trs20p and/or Trs33p). We used a larger complex that additionally contained Trs20p for guanosine nucleotide-exchange assays. This second complex contains all essential TRAPPI subunits and was reported (A) Protein A-tagged TRAPPI and TRAPPII were prepared as described in the Supplemental Data. The GEF activity on Ypt1p, stimulated by TRAPPI and TRAPPII, was normalized to Trs33p. The assay is described in the Supplemental Data. The data shown were obtained from four separate experiments. Error bars are SEM. (B) Equivalent amounts of recombinant GST, GST-Ypt1p-GDP, and GSTYpt1p-GTP were loaded with nucleotide as described in Supplemental Data, incubated with yeast lysate as before (Wang et al., 2000) , and blotted for the TRAPPII-specific subunit Trs130p. (C) The TRAPPII complex, isolated as described above, was assayed for its ability to stimulate nucleotide exchange on Ypt31p and (D) Ypt32p. For comparison, an equivalent amount of TRAPPII was assayed for its ability to activate Ypt1p. The amount of TRAPPII assayed in (C) and (D) was not equivalent. Error bars are SEM.
to be indistinguishable from intact TRAPPI, as monitored by GDP release and GTP uptake assays (Kim et al., 2006; Cai et al., 2007b) .
For overexpression of TRAPPI subcomplexes, three Duet plasmids harboring genes for BET3, BET5, TRS23, TRS31, and optionally TRS20 were cotransformed into E. coli BL21(DE3) cells by electroporation. When the cells reached an OD 600 of $0.6-0.8, they were shifted to 25 C, and protein expression was induced with 0.5 mM IPTG. Cells were harvested 18 hr after induction. Selenomethionine-substituted protein was produced similarly, according to established protocols (Doublie, 1997) . TRAPPI subcomplex was purified by Ni-NTA chromatography (QIAGEN). Complexes used in guanine nucleotide-exchange assays were further purified by gel filtration on a Superdex-200 column (GE Healthcare) to remove the Bet3p/Trs31p heterodimer. The gel filtration buffer (A) contains 10 mM Tris (pH 8.0), 300 mM NaCl, and 1 mM DTT. Complexes used in crystallization were treated with TEV to remove the Trs31p hexahistidine tag.
His 6 -Ypt1p was also overexpressed in E. coli BL21(DE3) cells at 25 C, as was the selenomethionine-substituted Ypt1p, and purified using Ni-NTA resin (QIAGEN).
To prepare the His 6 -Ypt1p/TRAPPI complex for crystallization, a TRAPPI complex consisting of Bet3p, Bet5p, Trs23p, and Trs31p was incubated at room temperature overnight with a molar excess of His 6 -Ypt1p (residues 1-180) and 20 mM EDTA. EDTA strips magnesium and nucleotides from Ypt1p, thereby facilitating the formation of the Ypt1p/TRAPPI complex. Similar protocols have been used in purifying a number of other GTPase/GEF complexes (see Goldberg, 1998; Renault et al., 2001; or Delprato and Lambright, 2007) , and the EDTA treatment does not inactivate Ypt1p (Figures 4A and  4E ; Esters et al., 2001 ). The protein mixture was loaded onto a Superdex-200 column (GE Healthcare, in buffer A with 10 mM DTT) to separate the Ypt1p/TRAPPI complex from uncomplexed Ypt1p, excess Bet3p/Trs31p heterodimer, and TEV protease. Ni-NTA resin was used to separate His 6 -Ypt1p/ TRAPPI from TRAPPI. Protein was exchanged into buffer A and concentrated to $20 mg/ml.
Crystallization
Crystals of the selenomethionine-substituted Ypt1p/TRAPPI complex were grown at 22 C by the hanging-drop vapor diffusion method. Drops consisted of 1.5 ml each of protein solution and reservoir solution (100 mM MES [pH 6.5], 3%-5% [w/v] PEG 20,000, 3% [w/v] sorbitol, and 5 mM DTT). Crystals were crosslinked with glutaraldehyde (Heras and Martin, 2005) and then transferred through a solution of mother liquor augmented to contain 20% glycerol (v/v), mounted in nylon loops, and flash-frozen in liquid nitrogen (Rodgers, 2001 ). Data were collected at beamline 24-ID-C at the Advanced Photon Source, Argonne National Laboratory and processed with HKL2000 (Otwinowski and Minor, 1997) . Crystals belong to space group P2 1 (a = 115.1, b = 115.4, c = 290.1 Å , b = 90.3 ) and diffract to 3.7 Å . They show no evidence of twinning.
Data Collection and Structure Determination
For phasing, data sets were collected at the selenium edge and at a remote wavelength. To locate the selenium positions, we initially worked in a higher symmetry space group, P4 1 2 1 2, a strategy allowed by pseudosymmetry in the crystal lattice. Once the selenium positions had been located using SHELXD (Schneider and Sheldrick, 2002) , we worked in the P2 1 space group. One hundred selenium sites were used in calculating phases. The selenium positions were refined and initial density-modified phases calculated using SHARP (de La Fortelle and Bricogne, 1997) . There are four copies of each Ypt1p/TRAPPI complex in the asymmetric unit. The four copies were averaged using the RAVE suite of programs (Kleywegt et al., 2001) in conjunction with CCP4 (Collaborative Computational Project, 1994) for improved maps. Electron density maps used for model building were sharpened, with B-factors ranging between À55 and À100 Å 2 ( Figure S5) . In building the model, we were guided by the selenium positions, as well as by structures available for vertebrate subunits of TRAPP and for nucleotide-bound forms of Ypt1p/ Rab1a. Neither the Bet3p C termini nor the palmitoylate groups in the Bet3p-A channels were modeled initially, and they were added only during refinement. , 1997) . The structure was refined by iterative cycles of manual refitting, torsion angle dynamics, and B-factor refinement in CNS (Brunger et al., 1998) . Phi/psi restraints were placed on helical regions, and the four complexes in the asymmetric unit were restrained to be similar. Composite omit maps were a valuable tool in rebuilding, though high temperatures (4000 K) were necessary during the torsion angle dynamics in order to remove phase bias. One round of averaging was applied to the omit maps, and the averaged map was consulted for rebuilding. The density for the Bet3p C termini and the Bet3p-B palmitoylate groups is clear in all composite omit maps (see Figure S1 ). Final refinement statistics are shown in Table S1 .
Figures were prepared using the programs Ribbons (Carson, 1997) or Grasp (Nicholls, 1993) .
Transient Kinetic Analysis
Kinetic analysis of nucleotide binding and dissociation was done following established procedures (Hannemann et al., 2005) and is described in the Supplemental Data. Briefly, nucleotide binding to Ypt1p was measured from the fluorescence enhancement associated with Forster resonance energy transfer from Ypt1p tryptophan residues to bound mant-(N-methylanthraniloyl-) nucleotide (Invitrogen) after rapid mixing under pseudo-first-order conditions ([nucleotide] > > [Ypt1p] or [Ypt1p/TRAPPI]). GDP exchange from Ypt1p is limited by dissociation of bound GDP and was measured by quantitation of tritiated GDP using a filter-based binding assay (Wang et al., 2000) and/or from the fluorescence of mantGDP.
Nucleotide Exchange Assays and In Vitro Binding with TRAPPII Details are in the Supplemental Data.
